Mark Vergnano
Analyst · Barclays. Your line is open
Thanks, Mark. Turning to Fluoroproducts on the next slide, sales in the quarter were up 7% to $682 million, with volume up across the segment. Price improved modestly, which was offset by a small currency headwind. The headline story here continues to be our fourth generation low GWP refrigerant Opteon, where we see steady adoption in both mobile and stationary applications. Base refrigerant pricing has come off highs from earlier in the year, though, in total, we continue to experience solid demand for our portfolio of refrigerant products. On the polymer side of the business, we experienced volume growth despite supply constraints across several product lines, along with year-over-year price improvement. Fluoroproducts adjusted EBITDA was $182 million in the third quarter, up 15% from the same quarter a year ago. Margins expanded to 26.7% in the quarter, an approximate 200 basis point improvement from last year's third quarter. We continue to see the benefits of our pricing actions taken last year and into this year, offsetting modest refrigerant price declines and the impact of increased distribution and raw material costs. Let's review the Fluoroproducts performance drivers for Q3 in a bit more detail, starting with fluorochemicals. The conversion to low global warming potential refrigerants continues to drive demand for Opteon in mobile applications as well as Opteon blends for stationary applications. In the third quarter, we saw strong demand for Opteon result in overall volume growth, which more than offset modestly lower price on a year-over-year basis. Base refrigerant revenue continues to be flat on a year-over-year basis as currency and modest price erosion offset volume growth. As you know, base refrigerants in Europe have seen a lot of price volatility over the past year due to the large step down in the F-Gas quota that occurred this year. Following the large increase in price that began last year, base refrigerants now seem to be correcting to a lower price point. Let's move ahead now to fluoropolymers. In the quarter, volume was positive even with supply constraints and our profitability improved due to price actions taken in 2017 and 2018. In late October, we announced the expansion of our Teflon PFA polymer manufacturing capacity, which is already helping to alleviate some supply constraints for this product line. Demand for Teflon PFA used in cabling solutions, chemical processing, oil and gas and, most importantly, semiconductor manufacturing is growing rapidly. Our Teflon PFA enables semiconductor manufacturers to maximize chip yields by reducing contamination, while minimizing downtime and process variability. This capacity expansion has already resulted in a 15% increase in our manufacturing capacity of Teflon PFA, which we expect to reach 25% by year-end. Longer-term, we plan to double our PFA production capacity by 2021. Looking ahead, we continue to make progress toward the startup of our Opteon facility in Corpus Christi, Texas. We remain on track to complete this facility by the end of the year, with startup following soon after. The full-year outlook for Fluoroproducts remains healthy, with the normal seasonality of the business manifesting itself in a stronger first than second half, as expected. We anticipate margins to be solidly in the mid-20s for the full year, with some variation on a quarterly basis. This is despite a slowdown in second half auto builds across Europe and Asia and the anticipation of a more modest euro currency benefit. Turning to our Chemical Solutions segment on the next slide. Sales in the third quarter improved 5% to $155 million, driven by broad-based price increases across our mining solutions and performance chemicals and intermediates business lines. Third-quarter adjusted EBITDA of $24 million was up 33% from the same period last year and set a record for the Chemical Solutions segment. Adjusted EBITDA margins of 15.5% in the quarter were supported by the price increases we discussed on our second quarter earnings call, along with favorable raw material pass-throughs. Our current mining solutions facility continues to be sold-out and market conditions remain tight in the Americas. However, our facility is running efficiently to serve this demand and we remain confident in our ability to meet our customers’ needs. Moving to slide 10 to review our Titanium Technology segment. Sales of $791 million were modestly below last year's strong third-quarter performance as higher global average prices for Ti-Pure titanium dioxide were more than offset by lower volume. You may recall that last year’s third quarter was our second highest volume in the history of Titanium Technologies, reflecting a preference for Ti-Pure pigment, as well as some inventory build at our customers. We are now experiencing lower demand consistent with customer destocking as Ti-Pure prices stabilize across our end markets and regions. As you know, forecasting the timing of destocking at customers can be challenging. We expect the trend of softer demand will persist through the next quarter. In the third quarter, adjusted EBITDA improved 8% to $268 million. This resulted in a 270-basis point margin improvement to 33.9%. On a sequential basis, we held local prices for Ti-Pure, which were partially masked by unfavorable customer mix. We remain fully committed to our Ti-Pure value stabilization strategy and are currently in the process of working with our customers as we implement the commercial framework. Our strategy is playing out just as we expected. We published slides that go into more detail about our strategy back in September, but let me take a minute to quickly review the basis for our Ti-Pure Assured Value Agreement, or AVA, portion of the framework. These agreements are a new and different approach to sales contracts with our customers, which we believe is good for our customers and good for us. As we have said in the past, we expect a majority of Ti-Pure sales to fall under these contracts. Our AVA agreements provide our customers with long-term supply assurance and a predictable pricing mechanism. In return, we gain confidence and a commitment that our customers are focused on generating value through our mutual long-term relationship. We are currently working with our customers around the world to implement these AVA agreements as existing contracts allow. For the full-year 2018, we do anticipate volume declines consistent with customer destocking across all end markets, leading to a mid-single digit decline in volume year-over-year. This is, again, in comparison to a very robust 2017. Again, we continue to expect our local prices to remain stable through the year. Let's review our 2018 outlook on the next slide. As I said at the outset of the call and spoke to on the previous chart, we have experienced volume declines in our Titanium Technologies segment this quarter. As a result, and despite continued strength across our other two segments, we now believe that 2018 adjusted EBITDA will be within the lower half of our original guidance range or between $1.7 million and $1.78 billion. In line with our adjusted EBITDA outlook, we now anticipate free cash flow of approximately $650 million for the full-year 2018. However, given our share repurchases year-to-date, we expect our adjusted EPS outlook to be within the top half of our $5.10 to $5.85 per share range. Turning to slide 12, our targets through 2020 remain unchanged. When we established these targets, we did so to reinforce the longer-term nature of the strategies we are implementing, from Ti-Pure value stabilization to Opteon growth to fluoropolymers application development. These are programs designed to drive growth and create long-term value for the company and our investors. We remain confident that these are the right strategies individually for each business and collectively for Chemours. As a team, we approach each of these strategies with the same resolve we brought to the five-point transformation plan and are committed to achieving our goals, irrespective of any near-term headwinds that we might face. In closing, I am proud to lead the 7,000 highly talented men and women of Chemours. In 2015, we set out to create a different kind of chemical company and I believe we are doing that each and every day. We are taking on large challenges at Chemours, but we have the best assets, process technology and, most importantly, the right people to achieve our goals. With that, we are happy to take your questions.